Euroasian journal of hepato-gastroenterology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  14 (2024)
Volume  13 (2023)
Volume  12 (2022)
Volume  11 (2021)
Volume  10 (2020)
Volume  9 (2019)
Volume  8 (2018)
Volume  7 (2017)
Volume  6 (2016)
Volume  5 (2015)
Volume  4 (2014)
Volume  3 (2013)
Volume  2 (2012)
Volume  1 (2011)
Related articles

VOLUME 13 , ISSUE 2 ( July-December, 2023 ) > List of Articles

Original Article

Detection of Primary Hepatocellular Carcinoma on18F-Fluorodeoxyglucose Positron Emission Tomography-computed Tomography

Kiran Arshad, Sheikh Danial Hanan, Muhammad Numair Younis, Rimsha Badar, Minahil Imran, Nefal Numair, Abubakar Imran

Keywords : Computed tomography, Hepatocellular carcinoma, 18F-flourodeoxyglucose positron emission tomography-computed tomography, Sensitivity

Citation Information : Arshad K, Hanan SD, Younis MN, Badar R, Imran M, Numair N, Imran A. Detection of Primary Hepatocellular Carcinoma on18F-Fluorodeoxyglucose Positron Emission Tomography-computed Tomography. Euroasian J Hepatogastroenterol 2023; 13 (2):66-72.

DOI: 10.5005/jp-journals-10018-1409

License: CC BY-NC 4.0

Published Online: 26-12-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Abstract

Aims and background: Hepatocellular carcinoma (HCC), ranks as the third most prevalent malignancy contributing to cancer-related death on a global scale. Hepatocellular carcinoma is known to be the fifth most frequently diagnosed malignancy of the males while among females, it is ranked as the seventh most common malignancy. The study was conducted to detect the sensitivity of primary HCC using18F-flourodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) scan. Materials and methods: This prospective study was conducted to identify the primary HCC in a sample size of 51 patients, in whom FDG PET-CT scan was performed between May 2022 and December 2022. Results: Among the cohort of 51 patients, primary HCC was detected on FDG PET-CT in 43 individuals representing true-positive cases. Conversely, FDG PET-CT was unable to detect HCC in 8 cases, representing false-negative. Out of 51 patients, 74.5% of HCC cases exhibited multifocal pattern. The maximum standardized uptake value (SUV max) of the primary malignant site ranged from 1.9 to 16.1, with a mean of 3.7 ± 2.8. The FDG PET-CT revealed abnormal sites of the uptake outside liver in 23 individuals. The research confirmed the tumor recurrence in four previously treated patients. In the conducted investigation, FDG PET-CT showed 84.3% sensitivity for the diagnosis of HCC. Conclusion: The study demonstrates that FDG PET-CT is a viable option for the detection of HCC. The sensitivity of FDG PET-CT in our population is comparable and in agreement with international data for diagnosis of HCC thereby favoring its reproducibility among geographical and ethnic groups. However, owing to the reduced ability of FDG PET-CT scan to identify well-differentiated/low-grade HCC, the routine use of FDG PET-CT scan may not be considered in cases requiring evaluation of primary disease only.

HTML PDF Share
  1. Wong SC, Ngai WT, Choi FPT. Update on positron emission tomography for hepatocellular carcinoma. Vol. 20, Hong Kong Journal of Radiology. Hong Kong Academy of Medicine Press; 2017. pp. 192–204. DOI: 10.12809/hkjr1716921.
  2. Kuker RA, Mesoloras G, Gulec SA. Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease. Int Semin Surg Oncol 2007;4:1–5. DOI: 10.1186/1477-7800-4-17.
  3. Cho Y, Lee DH, Lee Y Bin, et al. Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma? PLoS One 2014;9(8):1–7. DOI: 10.1371/journal.pone.0105679.
  4. Shen C, Jiang X, Li M, et al. Hepatitis virus and hepatocellular carcinoma: Recent advances. Cancers (Basel) 2023;15(2):533. DOI: 10.3390/cancers15020533.
  5. Ozakyol A. Global epidemiology of hepatocellular carcinoma (HCC epidemiology). J Gastrointest Cancer 2017;48(3):238–240. DOI: 10.1007/s12029-017-9959-0.
  6. World Health Organization (WHO). Globocan 2020 Pakistan report. Glob Cancer Obs 2021;928:2020–1.
  7. Tahir M. Hepatocellular carcinoma: Hope and challenges. Liaquat Natl J Cancer Care 2022;3(1):1–2. DOI: https://doi.org/10.37184/lnjcc.2789-0112.3.8.
  8. Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog 2017;16:1. DOI: 10.4103/jcar.JCar_9_16.
  9. Lu RC, She B, Gao WT, et al. Positron-emission tomography for hepatocellular carcinoma: Current status and future prospects. World J Gastroenterol 2019;25(32):4682–95. DOI: 10.3748/wjg.v25.i32.4682.
  10. Butt AS, Abbas Z, Jafri W. Hepatocellular carcinoma in Pakistan: Where do We Stand? Hepat Mon 2012;12(10). DOI: 10.5812/hepatmon.6023.
  11. Rich NE, John BV, Parikh ND, et al. Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multicenter cohort of patients with cirrhosis. Hepatology 2020;72(5):1654–1665. DOI: 10.1002/hep.31159.
  12. Chartampilas E, Rafailidis V, Georgopoulou V, et al. Current imaging diagnosis of hepatocellular carcinoma. Cancers (Basel) 2022;14(16):3997. DOI: 10.3390/cancers14163997.
  13. Ronot M, Vilgrain V. Hepatocellular carcinoma: Diagnostic criteria by imaging techniques. Best Pract Res Clin Gastroenterol 2014;28(5): 795–812. DOI: 10.1016/j.bpg.2014.08.005.
  14. Arif-Tiwari H, Kalb B, Chundru S, et al. MRI of hepatocellular carcinoma: an update of current practices. Diagn Interv Radiol [Internet] 2014;20(3):209–221. DOI: 10.5152/dir.2014.13370.
  15. Parra NS, Ross HM, Khan A, et al. Advancements in the Diagnosis of Hepatocellular Carcinoma. Int J Transl Med 2023;3(1):51–65. DOI: 10.3390/ijtm3010005.
  16. Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015;42(2):328–354. DOI: 10.1007/s00259-014-2961-x.
  17. Bhatti ABH, Dar FS, Waheed A, et al. Hepatocellular carcinoma in Pakistan: National Trends and Global Perspective. Gastroenterol Res Pract 2016;2016:5942306. DOI: 10.1155/2016/5942306.
  18. Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: A systematic review. Br J Cancer 2007;96(7):1127–1134. DOI: 10.1038/sj.bjc.6603649.
  19. Butt AS, Hamid S, Wadalawala AA, et al. Hepatocellular carcinoma in Native South Asian Pakistani population; Trends, clinico-pathological characteristics and differences in viral marker negative and viral-hepatocellular carcinoma. BMC Res Notes 2013;6:137. DOI: 10.1186/1756-0500-6-137.
  20. Khokhar N, Aijazi I, Gill ML. Spectrum of hepatocellular carcinoma at Shifa International Hospital, Islamabad. J Ayub Med Coll Abbottabad 2003;15(4):1–4. PMID: 15067821.
  21. Raza A, Sood GK. Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J Gastroenterol 2014;20(15):4115–4127. DOI: 10.3748/wjg.v20.i15.4115.
  22. Abdelhalim H, Houseni M, Elsakhawy M, et al. Role of 18F-FDG PET-CT in initial staging of hepatocellular carcinoma and its impact on changing clinical decision. Egypt Liver J 2020;10(1). DOI: 10.1186/s43066-019-0012-9.
  23. Fattahi N, Rezaei N, Asadi-Lari M, et al. Hepatocellular carcinoma incidence at national and provincial levels in Iran from 2000 to 2016: A meta-regression analysis. PLoS One 2021;16(1):e0245468. DOI: 10.1371/journal.pone.0245468.
  24. Kim SH, Won KS, Choi BW, et al. Usefulness of F-18 FDG PET/CT in the evaluation of early treatment response after interventional therapy for hepatocellular carcinoma. Nucl Med Mol Imaging 2012;46(2): 102–110. DOI: 10.1007/s13139-012-0138-8.
  25. Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000;32(5):792–797. DOI: 10.1016/s0168-8278(00)80248-2.
  26. Park JC, Park JG, Jung GS, et al. Usefulness of 18F-FDG PET/CT and multiphase CT in the differential diagnosis of hepatocellular carcinoma and combined hepatocellular carcinoma-cholangiocarcinoma. Taehan Yongsang Uihakhoe Chi 2020;81(6):1424–1435. DOI: 10.3348/jksr.2019.0154.
  27. Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999;94(11):3314–3319. DOI: 10.1111/j.1572-0241.1999.01544.x
  28. Abdel Rahman AS, ZAAMD MD, Hassan Allam YE. Diagnostic Role of PET CT in Hepatocellular Carcinoma Compaired with Triphasic CT Imaging. Med J Cairo Univ 2021;89(12):2851–2857.
  29. Gomaa MI. Role of 18-FDG/PET in evaluation of hepatocellular carcinoma managed locally by transarterial chemoembolization compared to triphasic computed tomography. 2020;8. DOI: https://doi.org/10.1186/s43055-020-00229-8.
  30. Hetta WM, Atyia HR. Role of PET CT in comparison to triphasic CT in early follow-up of hepatocellular carcinoma after transarterial chemoemoblization. Egypt J Radiol Nucl Med 2020;51(1):33. DOI: https://doi.org/10.1186/s43055-020-0150-4.
  31. Farahat M, Mohamed A, Taha N. Role of Pet/Ct in evaluation of hepatocellular carcinoma after radiofrequency ablation. Ain Shams Med J 2022;73(1):43–55. DOI: 10.21608/ASMJ.2022.233514.
  32. Lee JE, Jang JY, Jeong SW, et al. Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan. World J Gastroenterol 2012;18(23):2979–2987. DOI: 10.3748/wjg.v18.i23.2979.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.